CSCO乳腺癌診療指南更新！綠葉製藥(02186.HK)紫杉醇脂質體獲Her2陰性晚期乳腺癌一線解救化療推薦
中國腫瘤學權威機構——中國臨牀腫瘤學會乳腺癌(CSCO BC)專家委員會於近期在線發佈《2020 CSCO乳腺癌診療指南》。綠葉製藥(02186.HK)自主研發的創新制劑——紫杉醇脂質體(力撲素®)獲得CSCO最新指南推薦，用於Her2陰性晚期乳腺癌一線解救化療。
《2020 CSCO乳腺癌診療指南》是國內極具影響力的乳腺癌診療指南，其內容的更新為中國乳腺癌診療提供了科學、規範的指引。指南指出：在Her2陰性復發轉移乳腺癌的治療中，對於既往“蒽環類治療失敗”或 “蒽環類和紫杉類治療失敗”的患者，推薦紫杉醇脂質體用於一線解救化療。
紫杉醇脂質體——力撲素®屬於紫杉醇納米制劑，是首個商業化的紫杉醇脂質體制劑，也是目前全球唯一上市的紫杉醇脂質體制劑，用於乳腺癌、非小細胞肺癌、卵巢癌的治療。該藥物獨特的腫瘤和淋巴結靶向性以及較長的半衰期，能更好地發揮抗腫瘤作用，同時獲得更好的安全性和耐受性。紫杉類藥物是治療乳腺癌最常用的藥物之一。在我國日常臨牀實踐中，紫杉醇脂質體的療效等同於溶劑型紫杉醇，而其血液毒性、神經毒性、肌肉關節疼痛、過敏反應等不良反應發生率更低，被認為是更安全的一類紫杉類藥物。
上市十六年來，紫杉醇脂質體的患者累計用藥超過200萬人次，其良好的療效和安全性已在長期臨牀應用中獲得廣泛認可，並相繼獲得多個權威指南和共識明確推薦。此前，紫杉醇脂質體已作為一線藥物被寫入《CSCO原發性肺癌診療指南(2019 版)》、並被納入《婦科惡性腫瘤紫杉類藥物臨牀應用專家共識》、《乳腺癌中紫杉類藥物臨牀應用專家共識(2020年)》中。此外，紫杉醇脂質體還作為多項放化療首選聯合用藥入選《中國食管癌放射治療指南(2019 版)》。
綠葉製藥集團管理層表示：“紫杉醇脂質體寫入2020 CSCO乳腺癌診療指南，將進一步提升該產品在相關適應症上的更廣泛應用，為更多患者帶來臨牀獲益。我們將繼續圍繞該產品的適應症拓展以及與其他藥物的聯合使用等方面積極開展各項上市後研究，為該藥物更好的應用於臨牀提供循證支持。”
CSCO指南由中國臨牀腫瘤學會指南工作委員會撰寫，在循證醫學和專家意見的基礎上，兼顧了地區發展不均衡所帶來的診療可及性差異，是中國臨牀醫生指導腫瘤臨牀診斷和治療的權威指南。《2020 CSCO乳腺癌診療指南》緊跟國際最新的科學研究進展，在2019 年版本的基礎上，基於臨牀研究證據，結合臨牀實踐經驗，更新形成了《2020年乳腺癌診療指南》。國際進展、中國貢獻、藥物可及成為該版《指南》更新的亮點。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
